Molecular basis for oncohistone H3 recognition by SETD2 methyltransferase

Genes and Development

Volumn 30, Issue 14, 2016, Pages 1611-1616

  Yang, Shuang ^a,b   Zheng, Xiangdong ^a,b   Lu, Chao ^c   Li, Guo Min ^b   Allis, C David ^c   Li, Haitao ^a,b,d  

^a TSINGHUA UNIVERSITY   (China)

^b Tsinghua University   (China)

^c ROCKEFELLER UNIVERSITY   (United States)

^d SICHUAN UNIVERSITY   (China)

Author keywords

Crystal structure; Epigenetic regulation; Oncohistone; SETD2 methyltransferase

Indexed keywords

HISTONE H3; METHYLTRANSFERASE; ONCOHISTONE H3; PROTEIN; S ADENOSYLHOMOCYSTEINE; SETD2 PROTEIN; UNCLASSIFIED DRUG; HISTONE; HISTONE LYSINE METHYLTRANSFERASE; PEPTIDE; PROTEIN BINDING; RECOMBINANT PROTEIN; SETD2 PROTEIN, MOUSE;

ARTICLE; BIOCHEMICAL ANALYSIS; CHONDROBLASTOMA; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; HUMAN; MOLECULAR BIOLOGY; MOLECULAR RECOGNITION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN STRUCTURE; STRUCTURE ANALYSIS; CHEMISTRY; CRYSTALLIZATION; ENZYME ACTIVATION; ENZYMOLOGY; ESCHERICHIA COLI; GENETICS; METABOLISM; MOLECULAR MODEL; MUTATION; PATHOPHYSIOLOGY; PROTEIN QUATERNARY STRUCTURE; SARCOMA;

CATALYTIC DOMAIN; CHONDROBLASTOMA; CRYSTALLIZATION; ENZYME ACTIVATION; ESCHERICHIA COLI; HISTONE-LYSINE N-METHYLTRANSFERASE; HISTONES; HUMANS; MODELS, MOLECULAR; MUTATION; PEPTIDES; PROTEIN BINDING; PROTEIN STRUCTURE, QUATERNARY; RECOMBINANT PROTEINS; SARCOMA;

EID: 84980034076     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.284323.116     Document Type: Article

References (29)

1. Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung LW, Kapral GJ, Grosse-Kunstleve RW, et al. 2010. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr 66: 213-221.
2. An S, Yeo KJ, Jeon YH, Song JJ. 2011. Crystal structure of the human histone methyltransferase ASH1L catalytic domain and its implications for the regulatory mechanism. J Biol Chem 286: 8369-8374.
3. Behjati S, Tarpey PS, Presneau N, Scheipl S, Pillay N, Van Loo P, Wedge DC, Cooke SL, Gundem G, Davies H, et al. 2013. Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat Genet 45: 1479-1482.
4. Brandl M, Weiss MS, Jabs A, Suhnel J, Hilgenfeld R. 2001. C-H…π -interactions in proteins. J Mol Biol 307: 357-377.
5. Chan KM, Fang D, Gan H, Hashizume R, Yu C, Schroeder M, Gupta N, Mueller S, James CD, Jenkins R, et al. 2013. The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. Genes Dev 27: 985-990.
6. Cheng Z, Cheung P, Kuo AJ, Yukl ET, Wilmot CM, Gozani O, Patel DJ. 2014. A molecular threading mechanism underlies Jumonji lysine demethylase KDM2A regulation of methylated H3K36. Genes Dev 28: 1758-1771.
7. Dawson MA, Kouzarides T. 2012. Cancer epigenetics: from mechanism to therapy. Cell 150: 12-27.
8. de Almeida SF, Grosso AR, Koch F, Fenouil R, Carvalho S, Andrade J, Levezinho H, Gut M, Eick D, Gut I, et al. 2011. Splicing enhances recruitment of methyltransferase HYPB/Setd2 and methylation of histone H3 Lys36. Nat Struct Mol Biol 18: 977-983.
9. Edmunds JW, Mahadevan LC, Clayton AL. 2008. Dynamic histone H3 methylation during gene induction: HYPB/Setd2 mediates all H3K36 trimethylation. EMBO J 27: 406-420.
10. Emsley P, Cowtan K. 2004. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60: 2126-2132.
11. Fang D, Gan H, Lee JH, Han J, Wang Z, Riester SM, Jin L, Chen J, Zhou H, Wang J, et al. 2016. The histone H3.3K36M mutation reprograms the epigenome of chondroblastomas. Science 352: 1344-1348.
12. Hu M, Sun XJ, Zhang YL, Kuang Y, Hu CQ, Wu WL, Shen SH, Du TT, Li H, He F, et al. 2010. Histone H3 lysine 36 methyltransferase Hypb is required for embryonic vascular remodeling. Proc Natl Acad Sci 107: 2956-2961.
13. Jayaram H, Hoelper D, Jain SU, Cantone N, Lundgren SM, Poy F, Allis CD, Cummings R, Bellon S, Lewis PW. 2016. S-adenosyl methionine is necessary for inhibition of the methyltransferase G9a by the lysine 9 to methionine mutation on histone H3. Proc Natl Acad Sci 113: 6182-6187.
14. Justin N, Zhang Y, Tarricone C, Martin SR, Chen S, Underwood E, De Marco V, Haire LF, Walker PA, Reinberg D, et al. 2016. Structural basis of oncogenic histone H3K27M inhibition of human polycomb repressive complex 2. Nat Commun 7: 11316.
15. Kim S, Kim H, Fong N, Erickson B, Bentley DL. 2011. Pre-mRNA splicing is a determinant of histone H3K36 methylation. Proc Natl Acad Sci 108: 13564-13569.
16. Laskowski RA, Swindells MB. 2011. LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. J Chem Inf Model 51: 2778-2786.
17. Lewis PW, Muller MM, Koletsky MS, Cordero F, Lin S, Banaszynski LA, Garcia BA, Muir TW, Becher OJ, Allis CD. 2013. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science 340: 857-861.
18. Li F, Mao G, Tong D, Huang J, Gu L, Yang W, Li GM. 2013. The histone mark H3K36me3 regulates human DNA mismatch repair through its interaction with MutSα. Cell 153: 590-600.
19. Lu C, Jain SU, Hoelper D, Bechet D, Molden RC, Ran L, Murphy D, Venneti S, Hameed M, Pawel BR, et al. 2016. Histone H3K36 mutations promote sarcomagenesis through altered histone methylation landscape. Science 352: 844-849.
20. Pai CC, Deegan RS, Subramanian L, Gal C, Sarkar S, Blaikley EJ, Walker C, Hulme L, Bernhard E, Codlin S, et al. 2014. A histone H3K36 chromatin switch coordinates DNA double-strand break repair pathway choice. Nat Commun 5: 4091.
21. Qiao Q, Li Y, Chen Z, Wang M, Reinberg D, Xu RM. 2011. The structure of NSD1 reveals an autoregulatory mechanism underlying histone H3K36 methylation. J Biol Chem 286: 8361-8368.
22. Schwartzentruber J, Korshunov A, Liu XY, Jones DT, Pfaff E, Jacob K, Sturm D, Fontebasso AM, Quang DA, Tonjes M, et al. 2012. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482: 226-231.
23. Shah MA, Denton EL, Arrowsmith CH, Lupien M, Schapira M. 2014. A global assessment of cancer genomic alterations in epigenetic mechanisms. Epigenetics Chromatin 7: 29.
24. Vagin A, Teplyakov A. 2010. Molecular replacement with MOLREP. Acta Crystallogr D Biol Crystallogr 66: 22-25.
25. Valley CC, Cembran A, Perlmutter JD, Lewis AK, Labello NP, Gao J, Sachs JN. 2012. The methionine-aromatic motif plays a unique role in stabilizing protein structure. J Biol Chem 287: 34979-34991.
26. Wagner EJ, Carpenter PB. 2012. Understanding the language of Lys36 methylation at histone H3. Nat Rev Mol Cell Biol 13: 115-126.
27. Wu G, Broniscer A, McEachron TA, Lu C, Paugh BS, Becksfort J, Qu C, Ding L, Huether R, Parker M, et al. 2012. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet 44: 251-253.
28. Yoh SM, Lucas JS, Jones KA. 2008. The Iws1:Spt6:CTD complex controls cotranscriptional mRNA biosynthesis and HYPB/Setd2-mediated histone H3K36 methylation. Genes Dev 22: 3422-3434.
29. Zheng W, Ibanez G, Wu H, Blum G, Zeng H, Dong A, Li F, Hajian T, Allali-Hassani A, Amaya MF, et al. 2012. Sinefungin derivatives as inhibitors and structure probes of protein lysine methyltransferase SETD2. J Am Chem Soc 134: 18004-18014.